Dr. Goy Discusses the Cost of CAR T-Cell Therapy

Andre Goy, MD, MS
Published: Friday, Jan 11, 2019



Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the cost of chimeric antigen receptor (CAR) T-cell therapy.

The cost of treatment—specifically with regard to CAR T-cell therapy—is an important aspect of oncology that needs to be considered, explains Goy. It is important that physicians work with payers to ensure that patients are able to derive the most benefit from available treatment modalities.

There are currently 2 CAR T-cell therapy products on the market: tisagenlecleucel (Kymriah) and axi-cel (axicabtagene ciloleucel; Yescarta). These products were approved by the FDA in May 2018 and October 2017, respectively, for patients with relapsed/refractory diffuse large B-cell lymphoma. However, many centers have waiting lists for these products because there is no reimbursement system in place, says Goy. However, as more products are developed, there is potential to develop outpatient CAR T cells which may increase the number of patients who could benefit from the therapy.
SELECTED
LANGUAGE


Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the cost of chimeric antigen receptor (CAR) T-cell therapy.

The cost of treatment—specifically with regard to CAR T-cell therapy—is an important aspect of oncology that needs to be considered, explains Goy. It is important that physicians work with payers to ensure that patients are able to derive the most benefit from available treatment modalities.

There are currently 2 CAR T-cell therapy products on the market: tisagenlecleucel (Kymriah) and axi-cel (axicabtagene ciloleucel; Yescarta). These products were approved by the FDA in May 2018 and October 2017, respectively, for patients with relapsed/refractory diffuse large B-cell lymphoma. However, many centers have waiting lists for these products because there is no reimbursement system in place, says Goy. However, as more products are developed, there is potential to develop outpatient CAR T cells which may increase the number of patients who could benefit from the therapy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x